# Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer

> **NCT00047762** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.**

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Erlotinib (aka Tarceva or OSI-774)
- **DRUG:** Bevacizumab (aka Avastin or Rhu MAb VEGF)

## Key facts

- **NCT ID:** NCT00047762
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00047762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00047762, "Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00047762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*